1. Introduction {#sec1}
===============

Parkinson\'s disease (PD) is characterized by the progressive loss of postmitotic dopaminergic neurons, whereas cancer results from uncontrolled cellular proliferation. Although PD and cancer are distinct diseases, a relationship between PD and cancer is well established. Epidemiological studies have shown that although most cancers are less frequent in PD compared with the general population ([@bib2], [@bib3], [@bib4], [@bib7], [@bib12], [@bib13]; [@bib16]; [@bib24], [@bib39], [@bib40], [@bib41], [@bib52]), cutaneous malignant melanoma (CMM) is found at an increased incidence in PD ([@bib2], [@bib3], [@bib4], [@bib24], [@bib41], [@bib52]). This well-documented association between CMM and PD is unexplained.

A genetic link between PD and CMM is supported by the demonstration of significant reciprocal risks of PD and CMM in cases and their relatives ([@bib16], [@bib17], [@bib24]). Although some support for a somatic genetic link between the 2 pathologies is provided by the role of Mendelian PD genes in CMM biology ([@bib5], [@bib25], [@bib28], [@bib31], [@bib35]), there is currently no direct evidence for shared genetic susceptibility between PD and CMM.

Some studies have assessed the reciprocal role of common (minor allele frequency \[MAF\] \> 1%) genetic variation in CMM and PD. Recently, it has been suggested that the CMM-associated *MC1R* variants p.R151C and p.R160W increase PD risk but their role still remains unclear ([@bib10], [@bib17], [@bib30], [@bib48]). Previous studies using genome-wide association study variants associated with PD or CMM have failed to show any genetic overlap ([@bib10], [@bib34]). More recently, rare de novo variants in the CMM risk gene *PTEN* have been implicated in PD ([@bib26]), but the role of rare coding variants underlying an association between PD and CMM has not yet been fully evaluated. Because the role of common genetic variation (variants with MAF \>1%) has already been substantially addressed, we focused our investigation into the proposed shared genetic background between these diseases on rare variants (MAF \<1%) in known CMM genes in 2 large independent PD case-control data sets as part of the International Parkinson\'s Disease Genomics Consortium.

2. Methods and materials {#sec2}
========================

2.1. Genetic analysis {#sec2.1}
---------------------

Using a systematic literature search, we identified susceptibility genes for CMM ([Supplementary Table 1](#appsec1){ref-type="sec"}). These included (1) germline high-risk genes associated with familial CMM (e.g., *CDKN2A*, *CDK4*); (2) germline common moderate-risk genes (e.g., *MC1R*); (3) genes commonly somatically mutated (e.g., *BRAF*); and (4) recently identified genes found to harbor rare somatic mutations ascribed to CMM (e.g., *TRRAP*, *DCC*). Genes were selected based on defined roles in inherited high-penetrance autosomal dominant disease (n = 2); an excess of somatic mutations (n = 20); an excess of common low-penetrance risk variants (n = 3); or combinations of these (n = 4). All rare (MAF \<1%) variants across these genes were assessed for enrichment in PD cases compared with unaffected controls.

We first assessed high-quality rare variant genotype data derived from the NeuroX chip on 6875 PD cases and 6065 controls (dbGaP Study Accession: phs000918.v1.p1). Briefly, the NeuroX chip has approximately 240,000 preselected variants based on standard Illumina exome content and over 24,000 custom content neurologic disease focused variants ([@bib37]).

We next assessed whole-exome sequencing data on 1255 PD cases and 473 controls from the International Parkinson\'s Disease Genomics Consortium. Briefly, sample libraries from cases and controls were prepared using either Roche Nimblegen (cases, n = 334; controls, n = 40) or Illumina (cases, n = 921; controls, n = 433) capture kits with paired-end sequencing performed on the Illumina HiSeq2000. Reads were aligned using Burrows-Wheeler Aligner ([@bib27]) against the University of California Santa Cruz (UCSC) hg19 reference genome. Variant calling and quality-based filtering were done using Genome Analysis Tool Kit (GATK) ([@bib32]). ANNOVAR ([@bib51]) was used to annotate variants with predicted impact of variants from the following in silico tools: SIFT ([@bib38]), PhyloP ([@bib44]), PolyPhen-2 ([@bib1]), LRT ([@bib6]), MutationTaster ([@bib45]), and GERP++ ([@bib8]).

Of the 29 identified CMM genes, only 24 were represented on the NeuroX panel ([Supplementary Table 1](#appsec1){ref-type="sec"}). Based on the annotated MAF data from 1000 Genomes Project (<http://www.1000genomes.org/>) and NHLBI GO Exome Sequencing Project (<https://evs.gs.washington.edu/EVS/>), all rare variants (MAF \< 1%) were extracted and assessed in PD cases and controls. We defined the potential deleterious impact of variants using previously defined methods ([@bib15], [@bib49]) with variants classified as damaging if ≥4 of the 6 in silico tools used predicted the change deleterious. Variants and samples with \>5% missing calls were excluded during QC.

All exome generated FastQs were run through the same pipeline and merged to generate high-quality genotype data. Damaging variants were defined as stated above. The GATK recommended filtering of variants, including the removal of variants with low coverage (read depth \<5), was implemented over and above the QC stated above. Post QC, 28 of the 29 selected CMM genes were covered by one or both captures methods ([Supplementary Table 1](#appsec1){ref-type="sec"}), and no difference between capture methods was observed with majority of all exons represented and included in the analyses ([Supplementary Table 2](#appsec1){ref-type="sec"}).

Candidate variants were also assessed in high-quality exome sequencing data generated from a CMM case-control cohort (CMM, n = 1298; Controls, n = 684) to investigate any reciprocal risks for CMM.

2.2. Statistical analysis {#sec2.2}
-------------------------

SNP-Set (Sequence) Kernel Association Test (SKAT) ([@bib53]) was used to test for association between the rare variants in genes and PD (gene- and gene set-based), adjusting for covariates including gender, coverage metrics and principal components (1--4). Dominant and recessive models of inheritance for each CMM gene were modeled and assessed using STATA (version 10; STATA, State College, TX, USA) via logistic regression, adjusting for covariates. For variants common to both cohorts, meta-analyses were conducted using standard methods modeling fixed effects ([@bib43]). Cochran\'s Q-statistic was calculated to test for heterogeneity (P~het~) ([@bib43]), and the I^2^ statistic ([@bib23]) was generated to quantify the proportion of the total variation caused by heterogeneity. Bonferroni\'s correction was applied, where applicable, to account for multiple testing.

3. Results {#sec3}
==========

3.1. Rare variant screening and burden analysis {#sec3.1}
-----------------------------------------------

The NeuroX data contained 237 variants with ≥1 nonreference allele after QC, including 215 (90.7%) nonsynonymous single nucleotide polymorphisms (nsSNPs), and 17 (7.2%) loss of function (LOF) variants (stop gains or losses, splice, frame- or nonframeshift indels). About 554 variants with ≥1 nonreference allele were extracted from exome sequencing data, including 268 (48.4%) synonymous, 269 (48.6%) nsSNPs, and 17 (3.0%) LOF variants. In the NeuroX data, 207 rare (MAF \<1%) variants were present in 23 of the 29 selected CMM genes, and 269 rare variants were observed in 25 genes in the exome.

When considering all the candidate genes at once, gene set--based SKAT analyses in the NeuroX data did not identify any significant difference in rare variation burden between PD cases and controls for all variants, or for each individual variant class ([Table 1](#tbl1){ref-type="table"}).

When considering all variation (including synonymous) within each gene individually ([Supplementary Table 3](#appsec1){ref-type="sec"}), no significant associations were seen in the NeuroX but nominally significant differences were identified for *AKT3* (P~skat~ = 0.049) and *BAP1* (P~skat~ = 0.004) in the exome cohort. A significant enrichment in *KIT* in the NeuroX was detected for rare, damaging nsSNPs (P~skat~ = 0.038) but was not seen in the exome data (P~skat~ = 0.571). A trend toward association was seen for *GRM* (P~skat~ = 0.075) in the Neurox data, and for *ERBB4* (P~skat~ = 0.055) and *TYR* (P~skat~ = 0.065) in the exome data. Although none survived correction for multiple testing, it does suggest possible case-control differences.

3.2. Case-control rare variant enrichment analysis {#sec3.2}
--------------------------------------------------

Dominant and recessive models were applied to LOF and/or nsSNPs variants within both PD data sets. Under a dominant model, no significant enrichment of carriers of rare nsSNPs was detected in the exome data. However, there was a nonsignificant increase in the number of carriers of dominant rare nsSNPs in 8 and 3 genes in both cases and controls, respectively. Similar results were seen in the NeuroX data, with 4/23 genes with suspected enrichment in cases and 4/23 genes in controls ([Table 2](#tbl2){ref-type="table"}). An increased number of carriers of rare *KIT* nsSNPs was detected in controls in NeuroX (OR~log~ = 0.68, 0.48--0.97, P~logreg~ = 0.035). The increased carrier frequency in controls is not consistent with the SKAT analysis, which suggested an increased burden of rare variants in cases. Two genes, *MITF* and *TP53*, also had increased number of carriers of rare alleles in controls compared to cases. Individual variant analysis within both data sets showed that no single variant within these genes was statistically enriched in controls ([Supplementary Tables 4 and 5](#appsec1){ref-type="sec"}).

Two genes, *MAP2K2* and *PTEN*, had enrichment of carriers of dominant variants in cases in both cohorts, suggesting that these variants could increase PD risk; although this analysis again relates to very rare alleles. Despite this, on an individual scale, all observed dominant variants within these 2 genes in both data sets also appeared enriched in cases ([Supplementary Tables 4 and 5](#appsec1){ref-type="sec"}).

Under a recessive model, although biallelic carriers of rare-damaging variants within the exome data were only seen in *DCC*, no significant difference was observed. In the NeuroX data, biallelic carriers appeared enriched in 4 genes, including *DCC* and *ERBB4*, although none reached significance ([Table 3](#tbl3){ref-type="table"}). No association with PD was detected for any individual rare variant in either cohort.

3.3. Rare variant meta-analyses {#sec3.3}
-------------------------------

The overlap between the NeuroX and exome data is limited to 70 variants. Meta-analyses revealed a single significant association with the p.A421A/splice variant in *DCC* (OR~meta~ = 0.87, 0.76--0.99; P~meta~ = 0.047) but was not significant following correction for multiple testing correction ([Supplementary Table 6](#appsec1){ref-type="sec"}).

Although no other significant association was seen, several variants were seen having ORs \>2. The very rare p.V275F variant in *TYR* (encoding Tyrosinase) appears to have the largest effect (OR~meta~ = 4.13, 0.72--23.62). Although this carrier frequency of this variant was higher in cases than controls in both cohorts (NeuroX: 0.12% vs. 0.02%; exome: 0.08% vs. 0%), we had limited statistical power (further suggested by very large CIs) to find a significant association even on combining cohorts (9/8095; 0.11% vs. 1/6533; 0.02%), which is likely due to the rareness of the p.V275F variant. This very rare variant was corroborated by Sanger sequencing in 5/5 samples available ([Supplementary Fig. 1](#appsec1){ref-type="sec"}). To further explore the role of p.V275F, we assessed carrier frequencies from an additional cohort of 642 PD exomes as well as data from ExAc consortium as a replication step (<http://exac.broadinstitute.org/>) ([Supplementary Table 7](#appsec1){ref-type="sec"}). Consistent with the other cohorts, there was an excess of V275F carriers in cases compared to controls (0.16% vs. 0.02%). Including this data, meta-analysis demonstrated that \>5-fold increased PD risk in p.V275F carriers (OR~meta~ = 5.42, 1.44--20.41; P~meta~ = 0.012) ([Supplementary Fig. 2](#appsec1){ref-type="sec"}). p.V275F was also investigated in CMM exome sequencing data, and no difference between CMM cases and controls was observed (2/1298; MAF = 0.08% vs. 1/685; MAF = 0.07%). Although preliminary, the data suggests that the p.V275F variant may have a role in PD etiology.

3.4. Known melanoma variant analysis {#sec3.4}
------------------------------------

Four and 5 variants definitively linked with CMM (germline or somatically) were present in exome and NeuroX data respectively. These variants were removed but had little effect on dominant and recessive models for all genes (data not shown). Individually, none of these variants were significantly associated with PD. Meta-analyses of the 2 variants present in both cohorts (p.A1276G in *GRIN2A* and p.E318K in *MITF*) were not found to influence PD risk.

4. Discussion {#sec4}
=============

Epidemiological evidence has consistently suggested a shared susceptibility to CMM and PD ([@bib2], [@bib3], [@bib4], [@bib7], [@bib12], [@bib13], [@bib16], [@bib17], [@bib24], [@bib39], [@bib40], [@bib41], [@bib52]). In this study, we investigated the role of rare variants in 29 CMM genes in PD risk using 2 large independent cohorts (exome-sequenced and SNP-genotyped) of PD cases and controls. Although our study is underpowered, as indicated by large confidence intervals, we have not identified a definitive overlap in genetic susceptibility in this large sample set. There was no increased burden of rare variants across all genes in either cohort. Gene-based comparisons identified a significant enrichment of rare, damaging *KIT* variants in cases in the NeuroX, data but this did not withstand correction for multiple testing. There was a trend toward enrichment of rare damaging variants in *GRM* in the NeuroX cases, and *ERBB4* and *TYR* in exome cases. There was no enrichment of rare nsSNPs in either cohort under a dominant model; however, there was a trend toward increased risk for *MAP2K2* and *PTEN*; and a trend toward reduced risk for *MITF* and *TP53*. Recessive biallelic carriers of *DCC* variants appeared over-represented in both cohorts. Interestingly, biallelic carriers of *ERBB4* variants were seen in 4/6875 NeuroX cases and 0/6605 controls ([Supplementary Table 8](#appsec1){ref-type="sec"}). Dominant mutations in *ERBB4* have previously been shown to cause amyotrophic lateral sclerosis (OMIM \#[615515](615515){#intref0025}) ([@bib47]) and therefore represents an attractive candidate gene for neurodegenerative disease in which recessive rare mutations may be linked to PD. Numerous individual variants were more common in cases rather than controls in either/both cohorts, with several genes showing high odds ratios on meta-analysis, although none was statistically significant.

Many rare moderate to high penetrant gene mutations cause PD (e.g., *LRRK2* and *PARK2*) or substantially increase PD risk (e.g., *GBA*) ([@bib29], [@bib46]). We investigated whether our results are modified by the presence/absence of known PD-linked variants within *LRRK2*, *PARK2*, and *GBA*. Removal of *LRRK2*, *PARK2*, or *GBA* variant carriers from both our dominant and recessive models did not change the overall results. No known PD mutations were found in any of the *TYR* p.V275F carriers.

Poor statistical power is an issue for all studies designed to uncover the genetics of complex diseases. It is becoming more evident that this is an issue for studies aimed at rare variant identification, and it has been proposed that studies such as this might need in excess of 25,000 discovery cases before adequate power is achieved ([@bib56]). Based on MAF = 1%, the exome data set only had 18.7% power to detect a 2-fold enrichment, and even lower power for even rarer MAFs. The NeuroX platform has been successfully used to identify several causative mutations in PD and other neurodegenerative diseases ([@bib18]). Despite being well powered to detect associations, the failure to replicate findings using the NeuroX platform is likely due to the fact that variants are preselected to focus specifically on genes/variants of interest to neurological disease ([@bib37]) and may therefore not be an accurate representation of variation across the CMM genes studied.

The very rare TYR p.V275F variant was more common in PD than controls in 3 independent data sets but not in CMM. Although all *TYR* p.V275F samples were successfully validated by Sanger sequencing, another potential concern is that not all variants investigated were confirmed by Sanger sequencing. This is particularly relevant to those genes which have a recognized pseudogene (e.g., *BRAF* and *PTEN*); however, stringent removal of reads mapping to other exonic locations would have restricted the inclusion of less secure genotypes in our analyses. The use of different capture methods in the exome data set represents a potential source of bias; however, stringent QC limited reads and variants seen in both captures across all samples thereby ensuring comparable high-quality genotype data. In addition, any systematic genotype bias should be present throughout the entire cohort as the same capture method was used for both cases and controls. The ExAc data represent samples collected for disease- and population-specific genetic studies and may therefore contain individuals with undiagnosed PD, which is likely to reduce any case-control differences. This suggests that our observed estimate may represent the lower bound of the true association.

The identification of a number of PD cases with the rare *TYR* p.V275F variant is of interest. Pigmentation genes contribute to CMM risk and have recently been proposed to contribute to PD ([@bib11], [@bib17], [@bib21], [@bib22], [@bib42]). The exact role of *TYR* and other pigmentation genes in CMM has yet to be fully elucidated. TYR activity correlates well with skin color with biallelic variants, including p.V275F, causing recessive oculocutaneous albinism 1B (OCA1B, OMIM \#[606952](606952){#intref0030}) due to reduced TYR activity. None of the carriers were found to harbor additional OCA1B-associated mutations and are unlikely to have albinism. Known to be expressed in the human substantia nigra ([@bib54]), tyrosinase is the rate-limiting enzyme in neuromelanin production as well as being responsible for the oxidation of L-tyrosine into L-DOPA during dopamine synthesis ([@bib14], [@bib42]). It has been proposed that neuromelanin has neuroprotective effects by preventing the accumulation of toxins ([@bib55]). So, reduced TYR activity may contribute to the loss of neurons due to increased cell toxicity independent of α-synuclein ([@bib20]). Dopamine receptor activation has been shown to reduce dopaminergic neuron death ([@bib36], [@bib50]). Therefore, reduced dopamine production may predispose nigral neurons to apoptosis. The observed enrichment of p.V275F in PD cases along with the recent demonstration that rare variants in *GCH1* are associated with PD ([@bib33]) provide further support for variation in the dopamine-biosynthetic pathway as being relevant to neurodegenerative PD.

5. Conclusions {#sec5}
==============

Evidence for a shared genetic background between CMM and PD has been provided by epidemiological studies. Biological evidence of an overlap between the 2 diseases is further suggested by the fact that melanocytes and neurons of the substantia nigra are both pigmented cells derived from the neural crest ([@bib19]); as well as that mitochondrial dysfunction is already implicated in both diseases ([@bib9]). Based on our study, the role of rare variants in CMM genes in PD etiology appears limited. However, the observed excess of carriers of the very rare *TYR* variant p.V275F in PD cases in 3 independent cohorts suggests an involvement in disease pathogenesis and strengthens previous proposals linking pigmentation genes to PD. In addition, the prospect of unidentified changes, genetic or epigenetic, in unknown genes conferring increased risk for both diseases cannot be excluded and remains to be further investigated.
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###### 

Gene set--based burden analysis for the types of rare variants observed across all studied cutaneous malignant melanoma genes in the Parkinson\'s NeuroX and exome cohorts

  Gene set tested                              NeuroX   Exome         
  -------------------------------------------- -------- ------- ----- -------
  All variation (incl. synonymous)             237      0.756   554   0.403
  All variation (excl. synonymous)             224      0.724   286   0.790
  All rare[a](#tbl1fna){ref-type="table-fn"}   206      0.948   269   0.693
  Germline[b](#tbl1fnb){ref-type="table-fn"}   65       0.913   57    0.599
  Somatic                                      197      0.665   255   0.795
  All LOF variants                             17       0.156   17    0.951
  Rare LOF variants                            16       0.321   16    0.999
  All nsSNPs                                   215      0.839   269   0.682
  Rare nsSNPs                                  198      0.963   253   0.586
  All damaging nsSNPs                          67       0.794   148   0.448
  Rare-damaging nsSNPs                         65       0.657   145   0.375
  All damaging nsSNPs and LOFs                 76       0.467   165   0.316
  Rare damaging nsSNPs and LOFs                67       0.444   162   0.656

Gene set--based SKAT analysis assessing the burden of rare variants in all candidate cutaneous malignant melanoma genes in Parkinson\'s disease cases and controls in 2 large independent cohorts from the International Parkinson\'s Disease Genomics Consortium.

Key: incl., including; excl., excluding; LOF, loss of function; N, number of variants assessed; nsSNPs, nonsynonymous single nucleotide polymorphisms; P~skat~, *p*-values generated from SKAT analyses, correcting for gender, coverage metrics and principal components (1--4).

Variants were classified as rare if their minor allele frequency was below 1%.

If germline variants have been described to be associated with melanoma then it is labeled "Germline".

###### 

Comparison of the number of cases and controls, who harbor dominant rare nonsynonymous variants in the studied cutaneous malignant melanoma genes in the NeuroX and exome Parkinson\'s disease case-control cohorts

  Gene       NeuroX   Exome                                                                                                                                             
  ---------- -------- ------------ ------- ------------ ---------- ----------------- ----------- ------- ------------ ------- ------------ ---------- ----------------- -----------
  *AKT3*                                                                                         1       0.0007       1       0.0021       1.28       0.08--20.76       0.864
  *BAP1*     *7*      *0.0010*     *10*    *0.0016*     *0.59*     *0.22--1.55*      *0.284*     4       0.0031       2       0.0042       0.95       0.15--6.14        0.953
  *BRAF*                                                                                         **3**   **0.0023**   **1**   **0.0021**   **1.64**   **0.16--16.60**   **0.675**
  *CDK4*     **14**   **0.0020**   **8**   **0.0013**   **1.49**   **0.62--3.59**    **0.370**   0       0            4       0.0084                                    
  *CDKN2A*   *37*     *0.0054*     *42*    *0.0069*     *0.75*     *0.48--1.17*      *0.210*     8       0.0063       3       0.0063       1.18       0.27--5.15        0.826
  *DCC*      198      0.0288       193     0.0318       0.91       0.74--1.11        0.334       58      0.0462       27      0.0570       0.83       0.49--1.40        0.478
  *EPHA2*    210      0.0305       199     0.0328       0.91       0.75--1.12        0.380       56      0.0446       21      0.0443       0.86       0.49--1.48        0.579
  *ERBB4*    50       0.0073       41      0.0068       1.02       0.67--1.54        0.942       17      0.0135       9       0.0190       0.63       0.26--1.55        0.316
  *GNA11*                                                                                        1       0.0007       1       0.0021       0.18       0.01--3.97        0.278
  *GNAQ*                                                                                                                                                                
  *GRIN2A*   254      0.0369       237     0.0391       0.94       0.78--1.12        0.490       74      0.0589       20      0.0422       1.08       0.63--1.87        0.774
  *GRM3*     **12**   **0.0017**   **5**   **0.0008**   **2.13**   **0.74--6.10**    **0.161**   6       0.0047       3       0.0063       0.78       0.18--3.34        0.741
  *HRAS*                                                                                         **2**   **0.0015**   **0**   **0**                                     
  *KIT*      *55*     *0.0080*     *70*    *0.0115*     *0.68*     *0.48--0.97*      *0.035*     *19*    *0.0151*     *10*    *0.0211*     *0.61*     *0.27--1.40*      *0.241*
  *MAP2K1*                                                                                       **2**   **0.0015**   **0**   **0**                                     
  *MAP2K2*   **3**    **0.0004**   **1**   **0.0002**   **2.08**   **0.22--20.03**   **0.526**   **1**   **0.0007**   **0**   **0**                                     
  *MC1R*     299      0.0435       254     0.0419       1.04       0.87--1.23        0.678       **4**   **0.0031**   **1**   **0.0021**   **2.02**   **0.22--18.50**   **0.536**
  *MDM2*     15       0.0022       8       0.0013       1.52       0.64--3.61        0.339                                                                              
  *MITF*     *37*     *0.0054*     *41*    *0.0068*     *0.77*     *0.49--1.21*      *0.258*     10      0.0079       5       0.0105       0.89       0.28--2.86        0.846
  *NRAS*                                                                                         **1**   **0.0007**   **0**   **0**                                     
  *PDGFRB*   213      0.0310       178     0.0293       1.05       0.86--1.29        0.625       44      0.0350       17      0.0359       1.04       0.56--1.94        0.909
  *PTEN*     **2**    **0.0003**   **1**   **0.0002**   **1.63**   **0.15--18.19**   **0.693**   **1**   **0.0007**   **0**   **0**                                     
  *STK11*    52       0.0076       51      0.0084       0.88       0.59--1.30        0.518       **1**   **0.0007**   **0**   **0**                                     
  *TERT*     70       0.0102       53      0.0087       1.14       0.79--1.63        0.487                                                                              
  *TP53*     *4*      *0.0006*     *10*    *0.0016*     *0.36*     *0.11--1.16*      *0.087*     *5*     *0.0039*     *2*     *0.0042*     *0.57*     *0.09--3.68*      *0.552*
  *TRRAP*    49       0.0071       49      0.0081       0.87       0.58--1.30        0.505       38      0.0302       12      0.0253       1.07       0.52--2.21        0.846
  *TYR*      28       0.0041       19      0.0031       1.32       0.74--2.38        0.348       25      0.0199       11      0.0232       0.93       0.43--2.01        0.856
  *XRCC3*    16       0.0023       10      0.0016       1.39       0.63--3.08        0.418       *2*     *0.0015*     *2*     *0.0042*     *0.54*     *0.07--4.20*      *0.553*
  *ZNF831*   105      0.0153       96      0.0158       0.97       0.73--1.29        0.840                                                                              

The number of cases harboring rare damaging^a^ dominant-acting variants were compared against that observed in the controls in both the Neurox and exome data sets.

Values in italics represent genes which have more carriers in controls than in cases.

Values in bold represent genes which have more carriers in cases than in controls.

Key: carriers, number of carriers of dominant rare damaging variants; CI, confidence intervals; Freq, frequency; n, number of samples; OR, odds ratio; P~loreg~, *p*-values generated from logistic regression, correcting for gender, coverage metrics, and principal components (1--4).

^a^Damaging variants are defined as all loss of function variants and those predicted to be deleterious by ≥4 of the 6 in silico tools used.

###### 

Cutaneous malignant melanoma genes demonstrating suggestive enrichment of cases harboring biallelic rare damaging[a](#tbl3fna){ref-type="table-fn"} variants under a recessive model in the NeuroX and exome Parkinson\'s disease case-control cohorts

  Gene      Exome   NeuroX                                                                                              
  --------- ------- -------- ----- -------- ------ ------------- ------- --- -------- --- -------- ------ ------------- -------
  *DCC*     3       0.0024   1     0.0021   1.54   0.14--16.96   0.726   2   0.0003   1   0.0002   1.60   0.14--17.75   0.702
  *EPHA2*   ---     ---      ---   ---      ---    ---           ---     2   0.0003   1   0.0002   1.52   0.14--16.98   0.733
  *ERBB4*   ---     ---      ---   ---      ---    ---           ---     4   0.0006   0   0        ---    ---           ---
  *MITF*    ---     ---      ---   ---      ---    ---           ---     1   0.0001   0   0        ---    ---           ---

The number of cases harboring biallelic (homozygous or compound heterozygous) rare damaging^a^ variants were compared against that observed in the controls in both the Neurox and exome data sets.

Key: carriers, number of carriers of biallelic rare damaging variants; CI, confidence intervals; Freq, frequency; n, number of samples; OR, odds ratio; P~loreg~, *p*-values generated from logistic regression, correcting for gender, coverage metrics, and principal components (1--4).

Damaging variants are defined as all loss of function variants and those predicted to be deleterious by ≥4 of the 6 in silico tools used.
